A peer-reviewed article in JACC: Advances has demonstrated that a risk prediction algorithm incorporating HeartBeam Inc.'s (NASDAQ: BEAT) credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%.
HeartBeam, a medical technology company focused on transforming cardiac care, said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The company's platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to the appropriate care outside of a medical facility.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. For more details on the intended use of its technology, refer to the company's cleared indications for use at https://www.heartbeam.com/indications.
The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. To view the full press release, visit https://ibn.fm/ainxV.
